Browsing Tag
ML-007C-MA
3 posts
Will ZEPHYR and IRIS data position MapLight Therapeutics, Inc. as a scalable CNS innovator?
MapLight Therapeutics nears dual CNS data readouts. Discover how ZEPHYR and IRIS could shape its strategy and market positioning.
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.
MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials
MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator.